GlassScriptPhysician profile
Michelle J Munroe
NPI 1861845240
$64,143.37
in general payments reported to CMS, 2019-2025
22 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,431 · 2022: $3,659 · 2023: $6,626 · 2024: $18K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $8,850 · Travel and Lodging: $6,822 · Food and Beverage: $4,904 · Education: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,035.00 |
| Consulting Fee | $8,850.00 |
| Travel and Lodging | $6,821.70 |
| Food and Beverage | $4,903.89 |
| Education | $442.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25,378.55 | 2021-2025 | Imfinzi, Tagrisso, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $13,066.82 | 2024-2025 | Alunbrig |
| Emd Serono, INC. | $9,857.76 | 2023-2025 | Bavencio, Tepmetko |
| Daiichi Sankyo INC. | $6,240.42 | 2023-2025 | Datroway, Enhertu |
| Janssen Biotech, INC. | $2,534.00 | 2023-2025 | Rybrevant |
| Pfizer INC. | $1,215.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $1,055.00 | 2022 | |
| Amgen INC. | $977.35 | 2021-2024 | Lumakras |
| Blueprint Medicines Corporation | $895.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $726.77 | 2021-2025 | Opdivo, Reblozyl |
| Lilly USA, LLC | $687.27 | 2021-2024 | Retevmo, Verzenio |
| Merck Sharp & Dohme LLC | $424.61 | 2021-2025 | Keytruda, Keytruda Qlex |
| G1 Therapeutics, INC. | $219.32 | 2022-2023 | Cosela |
| Genentech USA, INC. | $193.04 | 2022-2024 | Tecentriq, Alecensa, Rozlytrek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.50 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $156.24 | 2024 | Optune Lua (Novottf-200t) |
| Genmab U.S., INC. | $109.88 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $107.26 | 2021-2024 | Libtayo |
| Mirati Therapeutics, INC. | $61.15 | 2023 | Krazati |
| Novartis Pharmaceuticals Corporation | $25.03 | 2024 | |
| Pharmacosmos Therapeutics INC. | $23.80 | 2024 | Cosela |
| Celgene Corporation | $13.10 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Munroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.